Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Best Salvage Treatment for High-risk Relapsing Prostate Cancer (PEACE-9 - ESCALATE-RT) (ESCALATE-RT)

21. august 2026 opdateret af: Thomas Zilli, Ente Ospedaliero Cantonale, Bellinzona

PEACE-9 - ESCALATE-RT: A Phase III Randomized Study in Patients With High-risk PSA Relapse After Local Therapy Treated With Enzalutamide Plus Androgen Deprivation Therapy and Comparing MDT ± Pelvic Radiotherapy Versus no Further Treatment

The goal of this clinical trial is to learn if adding metastasis-directed radiotherapy with or without pelvic salvage radiotherapy, to intermittent prostate cancer drugs (intensified hormone therapy) can delay the need to restart these drugs in men with oligometastactic prostate cancer recurrence.

In practice, this study is open to men whose PSA level (a blood marker of cancer activity) is rising as defined by biochemical recurrence, and who have 1 to 5 areas of cancer spread (1 to 5 metastases defining oligometastatic status) found on a specialized scan (PSMA PET/CT).

Since intensified hormone therapy, including androgen deprivation therapy combined with a next-generation hormone therapy, represents the standard treatment strategy for these patients, researchers want to find out if adding radiation therapy can help patients to spend more time off cancer drugs while keeping their cancer under control.

The main questions this trial aims to answer are:

  • Does adding radiation therapy to each metastases with or without pelvic area, lengthen the time before participants need to restart drug treatment?
  • Does adding radiation therapy increase the number of participants whose PSA drops to a very low level (0.2 ng/mL or lower)?
  • Does adding radiation therapy affect participants' quality of life?

Researchers will randomly assign participants (chosen by chance) to receive either enzalutamide (next-generation hormone therapy) plus androgen-deprivation therapy (first-generation hormone therapy ) alone, or the same association of these drugs combined with radiation therapy aimed at each metastases with or without pelvic area.

This comparison will show whether adding radiation therapy helps participants reach a deeper PSA response and go longer without needing cancer drugs.

Participants will:

  • Take enzalutamide and androgen-deprivation therapy for 9 months
  • Have an equal chance of also receiving radiation therapy to each metastases with or without pelvic area
  • Stop drug treatment after 9 months if their PSA drops below 0.2 ng/mL, a level showing the cancer is well controlled
  • Restart drug treatment if their PSA rises again during the treatment-free period
  • Have regular blood tests and clinic visits to check their PSA, testosterone, and overall health
  • Complete short quality-of-life questionnaires during the study
  • Take part in a study conducted at several hospitals in Switzerland, Belgium, and France.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

140

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

  • Belgien
      • Aalst, Belgien
        • AZorg Aalst
        • Kontakt:
          • Mark De Ridder, MD
      • Antwerp, Belgien
        • Iridium Netwerk
        • Kontakt:
          • Piet Ost, MD, PhD
      • Bruges, Belgien
        • AZ Sint-Jan
        • Kontakt:
          • Sarah Roels, MD
      • Brussels, Belgien
        • Institut Bordet - HUB Brussel
        • Kontakt:
          • Dirk Van Gestel, MD
      • Hasselt, Belgien
        • Jessa Ziekenhuis
        • Kontakt:
          • Philippe Bulens, MD
      • Kortrijk, Belgien
        • AZ Groeninge
        • Kontakt:
          • Aurélie De Bruycker, MD
      • Mechelen, Belgien
        • AZ Sint-Maarten Mechelen
        • Kontakt:
          • Cédric Draulans, MD
  • Frankrig
      • Bordeaux, Frankrig
        • Institut Bergonie
        • Kontakt:
          • Vérane Achard, MD, PhD
      • Lille, Frankrig
        • Centre Oscar Lambret
        • Kontakt:
          • David Pasquier, MD, PhD
      • Saint-Etienne, Frankrig
      • Saint-Herblain, Frankrig
        • Institut de Cancérologie de l'Ouest
        • Kontakt:
          • Stéphane Supiot, MD, PhD
      • Villejuif, Frankrig
        • Institut Gustave Roussy
        • Kontakt:
          • Pierre Blanchard, MD, PhD
  • Schweiz

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  • Histologically proven initial diagnosis of adenocarcinoma of the prostate
  • Rising PSA after local therapy as defined by PSA ≥ 0.2 ng/mL after RP +/- adjuvant/salvage prostate bed RT and at least 2 ng/mL above nadir for primary RT, with a PSADT ≤ 9 months
  • Serum Testosterone ≥ 150 ng/dl (6.9343 nM/L)
  • On PSMA PET/CT restaging presence of: 1 to 5 distant metastases that are amenable to MDT ± N1 patients (no limit in the number of nodes)
  • ECOG performance status 0 - 2
  • Age > or =18 years
  • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
  • Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations

Exclusion Criteria:

  • More than 5 distant PSMA positive metastases and/or brain or leptomeningeal metastases.
  • Prostate recurrence (positive PSMA disease) after primary prostate irradiation
  • Prostate bed recurrence (positive PSMA disease) after salvage/adjuvant irradiation
  • Pelvic nodal recurrence (positive PSMA disease) after primary WPRT irradiation
  • Contraindications to pelvic RT and/or MDT
  • Prior evidence of distant metastatic disease
  • Contraindications to ADT
  • Contraindication for treatment with enzalutamide
  • Prior hormonal therapy (Neoadjuvant/adjuvant therapy to treat PCa ≤ 36 months in duration and ≥ 9 months before randomization is allowed)
  • Previous treatment with cytotoxic agent for PCa
  • Any active malignancies (i.e., progressing or requiring any treatment in the previous 36 months) other than prostate cancer (except non-muscle invasive bladder cancer; non-melanomatous skin cancer or a malignancy that is considered cured with minimal risk of recurrence

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: ADT plus Enzalutamide
Enzalutamide 160 mg daily + androgen deprivation therapy for 9 months, suspended if PSA < 0.2 ng/mL, followed by PSA monitoring until progression
Medicin: Androgen Deprivation Therapy (ADT)
  • All arms should receive ADT for a duration of at least 36 weeks.
  • The prescription of ADT in both treatment arms will be in accordance with standard practice for the indication, the chosen molecules, and the selected doses.

  • ADT should be suspended at the end of week 36, if PSA < 0.2 ng/mL at week 36. In the off-period, ADT will be restarted with a rise of PSA to ≥ 5 ng/mL after primary RT or to ≥ 2 ng/mL after RP ± postoperative RT. For patients in the off-period with rising PSA < 5 ng/mL after primary RT or < 2ng/mL after RP

    • postoperative RT, the decision to restart treatment is led to each investigator.
  • ADT should be continued until progression at the end of week 36, if PSA ≥ 0.2 ng/mL at week 36.
Medicin: Enzalutamide
  • All arms should receive enzalutamide 160mg daily for a duration of at least 36 weeks.
  • Enzalutamide should be suspended at the end of week 36, if PSA < 0.2 ng/mL at week 36. In the off-period, Enzalutamide will be restarted with a rise of PSA to ≥ 5 ng/mL after primary RT or to ≥ 2 ng/mL after RP ± postoperative RT. For patients in the off-period with rising PSA < 5 ng/mL after primary RT or < 2ng/mL after RP ± postoperative RT, the decision to restart treatment is led to each investigator.
  • Enzalutamide should be continued until progression at the end of week 36, if PSA ≥ 0.2 ng/mL at week 36.
Eksperimentel: ADT plus Enzalutamide plus Radiotherapy (MDT +/- WPRT)
Enzalutamide 160 mg daily + androgen deprivation therapy for 9 months, suspended if PSA < 0.2 ng/mL, followed by PSA monitoring until progression + Radiotherapy for MDT ± WPRT
Medicin: Androgen Deprivation Therapy (ADT)
  • All arms should receive ADT for a duration of at least 36 weeks.
  • The prescription of ADT in both treatment arms will be in accordance with standard practice for the indication, the chosen molecules, and the selected doses.

  • ADT should be suspended at the end of week 36, if PSA < 0.2 ng/mL at week 36. In the off-period, ADT will be restarted with a rise of PSA to ≥ 5 ng/mL after primary RT or to ≥ 2 ng/mL after RP ± postoperative RT. For patients in the off-period with rising PSA < 5 ng/mL after primary RT or < 2ng/mL after RP

    • postoperative RT, the decision to restart treatment is led to each investigator.
  • ADT should be continued until progression at the end of week 36, if PSA ≥ 0.2 ng/mL at week 36.
Medicin: Enzalutamide
  • All arms should receive enzalutamide 160mg daily for a duration of at least 36 weeks.
  • Enzalutamide should be suspended at the end of week 36, if PSA < 0.2 ng/mL at week 36. In the off-period, Enzalutamide will be restarted with a rise of PSA to ≥ 5 ng/mL after primary RT or to ≥ 2 ng/mL after RP ± postoperative RT. For patients in the off-period with rising PSA < 5 ng/mL after primary RT or < 2ng/mL after RP ± postoperative RT, the decision to restart treatment is led to each investigator.
  • Enzalutamide should be continued until progression at the end of week 36, if PSA ≥ 0.2 ng/mL at week 36.
Stråling: Radiotherapy for MDT ± WPRT

Participants receive metastasis-directed therapy (MDT) alone or combined with prostate-bed radiotherapy (PB-RT) and/or whole pelvic radiotherapy (WPRT), as follows (radiotherapy is tailored to each participant's prior curative treatment for prostate cancer, to avoid re-irradiating previously treated volumes) :

  • Prior radical prostatectomy (RP) alone: MDT plus PB-RT, with or without WPRT. WPRT is mandatory for pelvic nodal involvement (N1) and recommended for node-negative (N0) participants.
  • Prior RP plus PB-RT: MDT, with or without WPRT. WPRT is mandatory for N1 and recommended for N0 participants.
  • Prior RP plus PB-RT plus WPRT: MDT alone.
  • Prior definitive prostate radiotherapy (no prostatectomy): MDT, with or without WPRT. WPRT is mandatory for N1 and recommended for N0 participants.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to first re-initiation of treatment
Tidsramme: From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date

• Time to first re-initiation of treatment calculated from randomization to the occurrence of one of the following events:

  • PSA ≥ 0.2 ng/mL at week 36 (treatment is continued until progression),
  • For patients in the off-period, a rise of PSA to ≥ 5 ng/mL after primary RT or to ≥ 2 ng/mL after RP ± postoperative RT (treatment is restarted as per EMBARK criteria)
  • For patients in the off-period with rising PSA < 5 ng/mL after primary RT or <2ng/mL after RP ± postoperative RT, the investigator decision to start same or new treatment.

Death in the absence of progressive disease will be considered as a competing risk for this endpoint.
From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to PSA progression
Tidsramme: From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
Time to PSA progression: defined by the time from the day of PSA nadir and the day when the PSA increase of ≥ 25% and an absolute increase of ≥ 2 ng/mL above the nadir.
From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
PFS (Progression-Free Survival)
Tidsramme: From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
PFS: defined as the time from randomization to the first progression or death (progression being defined by the appearance of a new recurrence (any N1 or M1) as suggested by PET-CT, or symptoms related to progressive prostate cancer, or death due to any cause).
From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
MFS (Metastasis-Free Survival)
Tidsramme: From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
MFS: defined as time between randomization and the appearance of a new metastatic recurrence (any M1) as suggested by PET-CT, or death due to any cause.
From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
OS (Overall Survival)
Tidsramme: From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
OS: defined as the time from randomization to death to any cause.
From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
PSA response
Tidsramme: From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
PSA response: defined by a PSA < 0.2 ng/ml at 9 months.
From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
Pattern of progression
Tidsramme: From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date

Local/regional/distant recurrence will be analyzed:

  • A local recurrence is defined as the appearance of evidence of a recurrence on imaging inside a PTV_M volume or the PTV_PB volume or the PTV_LNN.
  • A regional nodal recurrence is defined as the appearance of evidence of a lymphadenopathy in the pelvis but outside the PTV_LNN volume, in a patient without the diagnosis of hematologic/lymphatic disorder associated with lymphadenopathy or if there is histopathological evidence.
  • Distant recurrence is defined as the appearance of evidence of a lymphadenopathy outside the PTV_LNN and outside all the PTV_M (for lymph nodes previously treated as metastasis), or distant metastases (M1b, M1c) outside all the PTV_M.
From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
Time to castration-resistant disease
Tidsramme: From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
Time to castration-resistant disease is defined as the time from trial randomization until castration-resistant status, defined as a castrate serum testosterone level below 50 ng/dL (1.7 nmol/L) plus either biochemical progression or radiological progression. Biochemical progression is defined as three consecutive rises in PSA at least 1 week apart, resulting in two 50% increases over the nadir, with a PSA level above 2 ng/mL. Radiological progression is defined as the appearance of two or more new bone lesions on bone scan, or enlargement of a soft tissue lesion using RECIST (Response Evaluation Criteria in Solid Tumours). Symptomatic progression alone is not sufficient to diagnose castration-resistant prostate cancer (CRPC).
From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
Adverse events
Tidsramme: From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
Adverse events: acute (during the first 3 months after the end of MDT ± WPRT and late (3 months after the end of MDT ± WPRT).
From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
Quality of life (QoL) - EORTC QLQ-C30
Tidsramme: From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
EORTC Quality of Life Questionnaire Core 30 (QLQ-C30), version 3, a 30-item questionnaire. Items are rated on a 4-point scale (1 = "Not at all" to 4 = "Very much"), except the two global health status/QoL items, rated on a 7-point scale (1 = "Very poor" to 7 = "Excellent"). Raw scores are linearly transformed to a 0-100 scale. Higher scores indicate better functioning/quality of life on the functional and global health scales, and greater symptom burden on the symptom scales.
From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
Quality of Life - EORTC QLQ-PR25
Tidsramme: From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
EORTC Quality of Life Questionnaire Prostate Cancer Module (QLQ-PR25), a 25-item module supplementing the QLQ-C30. Items are rated on a 4-point scale (1 = "Not at all" to 4 = "Very much"). Raw scores are linearly transformed to a 0-100 scale. Higher scores indicate greater symptom burden, except for sexual activity/functioning scales, where higher scores indicate better functioning.
From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
Quality of Life - EORTC IL-249
Tidsramme: From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
A customised 22-item list from the EORTC IL-249, assessing general symptoms, weight-related issues, and sexual quality of life. Items are rated on a 4-point scale (1 = "Not at all" to 4 = "Very much"). Raw scores are linearly transformed to a 0-100 scale; higher scores indicate a greater burden of symptoms or issues.
From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Ente Ospedaliero Cantonale, Bellinzona

Samarbejdspartnere

Clinical Trial Unit Ente Ospedaliero Cantonale

Efterforskere

  • Ledende efterforsker: Thomas Zilli, MD, IOSI-EOC
  • Studiestol: Bertrand Tombal, MD, PhD, Urology, Cliniques Universitaires Saint Luc, Bruxelles, Belgium
  • Studiestol: Piet Ost, MD, PhD, Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Department of Radiation Oncology, Iridium Network, Wilrijk, Belgium
  • Studiestol: Silke Gillessen, MD, IOSI-EOC
  • Studiestol: Piet Dirix, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Belgium
  • Studiestol: Salvatore Cozzi, MD, IOSI-EOC
  • Studiestol: Nicolas Vial, MD, University Hospital of Saint-Etienne

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. november 2026

Primær færdiggørelse (Anslået)

1. juli 2030

Studieafslutning (Anslået)

1. juli 2030

Datoer for studieregistrering

Først indsendt

19. august 2026

Først indsendt, der opfyldte QC-kriterier

21. august 2026

Først opslået (Faktiske)

24. august 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

24. august 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

21. august 2026

Sidst verificeret

1. august 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • PEACE-9 - ESCALATE-RT

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner